Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Rhea-AI Summary

Jasper Therapeutics (NASDAQ:JSPR) will host an investor webinar on Tuesday, December 2, 2025 at 8:00 am ET to present preliminary ETESIAN asthma data and findings from its investigation into anomalous BEACON CSU results reported in July. The session will include remarks from Jasper management and Dr. Martin Metz, M.D., lead EU investigator in BEACON, followed by a live Q&A. Registration is required and presentation slides plus live and archived webcast links will be posted on Jasper's Investor Relations Events page.

News Market Reaction

-6.52% 119.4x vol

15 alerts

-6.52% News Effect

+34.1% Peak Tracked

-25.5% Trough Tracked

-$3M Valuation Impact

$48M Market Cap

119.4x Rel. Volume

On the day this news was published, JSPR declined 6.52%, reflecting a notable negative market reaction. Argus tracked a peak move of +34.1% during that session. Argus tracked a trough of -25.5% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $48M at that time. Trading volume was exceptionally heavy at 119.4x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webinar date: December 2, 2025 Webinar time: 8:00 am ET

2 metrics

Webinar date December 2, 2025 Scheduled investor webinar on ETESIAN and BEACON

Webinar time 8:00 am ET Start time for the Jasper investor webinar

Market Reality Check

Price: $1.47 Vol: Volume 540,195 is well be...

low vol

$1.47 Last Close

Volume Volume 540,195 is well below the 20-day average of 3,790,865, suggesting limited positioning ahead of the webinar. low

Technical At $1.84, JSPR trades below its $3.65 200-day moving average, reflecting a longer-term downtrend despite today’s gain.

Peers on Argus

While JSPR was up 5.65%, key biotech peers like ESLA (-8.41%), LVTX (-3.87%), an...

While JSPR was up 5.65%, key biotech peers like ESLA (-8.41%), LVTX (-3.87%), and LTRN (-2.6%) were down, pointing to a stock-specific move rather than a sector-wide shift.

Historical Context

5 past events · Latest: Dec 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 02	Clinical data update	Positive	-8.1%	Positive ETESIAN asthma data and BEACON investigation closure reported.
Dec 01	Investor event notice	Neutral	-6.5%	Announcement of investor webinar on ETESIAN and BEACON findings.
Nov 10	Earnings and update	Negative	+0.0%	Q3 2025 loss, cash levels, and updates on BEACON and ETESIAN timelines.
Nov 04	Conference appearances	Neutral	-13.8%	Multiple investor conference presentations scheduled in Nov–Dec 2025.
Sep 19	Equity offering	Negative	-3.5%	$30M public offering of stock and warrants for briquilimab programs.

Pattern Detected

Recent news, including positive clinical updates and conference appearances, has often been followed by negative or flat price reactions, indicating a tendency for the stock to sell off or hesitate on ostensibly favorable headlines.

Recent Company History

Over the last few months, Jasper has balanced clinical progress in briquilimab with financing and restructuring. A $30M public offering in September 2025 and Q3 results highlighted ongoing losses and cash needs. Subsequent conference appearances and the ETESIAN/BEACON data update on Dec 2, 2025 were followed by negative price moves. Today’s webinar announcement, also tied to ETESIAN and BEACON, fits into this pattern of frequent data and investor updates against a challenging share-price backdrop.

Market Pulse Summary

The stock moved -6.5% in the session following this news. A negative reaction despite this schedulin...

Analysis

The stock moved -6.5% in the session following this news. A negative reaction despite this scheduling update would fit a pattern where Jasper’s shares often weakened around news, including conferences and clinical updates. Past events, such as the positive ETESIAN data on Dec 2, 2025, still saw the stock down over the following day. Investors may be focusing on broader concerns highlighted in recent filings, including ongoing losses and prior equity offerings, when responding to another communication tied to the ETESIAN and BEACON programs.

Key Terms

c-Kit, CD117, mast cell, chronic spontaneous urticaria, +1 more

5 terms

c-Kit medical

"briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address"

c-kit is a protein on the surface of certain cells that acts like a control switch, receiving signals that tell the cell to grow, divide, or survive; it is produced from the KIT gene. Changes in c-kit activity or its structure can drive some cancers or other disorders, so drugs that block or target c-kit — and tests that detect c-kit changes — are important for deciding which patients may benefit and for predicting clinical and commercial outcomes.

CD117 medical

"a novel antibody therapy targeting c-Kit (CD117) to address mast cell"

CD117, also called c-KIT, is a protein found on the surface of certain cells that acts like a signaling switch controlling growth and survival; think of it as a lock on the cell surface that, when activated, tells the cell to divide or stay alive. Investors care because abnormal CD117 activity is linked to specific cancers and blood disorders, making it a target for diagnostics and drugs—progress or setbacks in therapies tied to CD117 can affect biotech valuations.

mast cell medical

"to address mast cell driven diseases such as chronic spontaneous"

A mast cell is a type of immune cell that sits in tissues like skin and the lining of the lungs and gut and releases chemical signals—such as histamine—when it detects danger. Think of it as a neighborhood alarm that calls in inflammation or allergy responses; its actions can drive allergic reactions, chronic inflammation, or disease. Investors pay attention because mast cells are common targets for new drugs, diagnostics, and safety issues that can affect a therapy’s market potential and regulatory path.

chronic spontaneous urticaria medical

"mast cell driven diseases such as chronic spontaneous urticaria (CSU),"

A long-term condition that causes recurring, itchy hives and sometimes swelling that appear without a clear trigger, like an alarm that goes off unpredictably on its own. It matters to investors because its chronic nature creates ongoing demand for treatments, diagnostics and follow-on care, influencing pharmaceutical research priorities, drug market size, regulatory review timelines and healthcare cost projections.

chronic inducible urticaria medical

"and asthma, today announced that the Company will host a webinar"

A long-term skin condition that causes recurrent hives or swelling when exposed to specific triggers like cold, heat, pressure, sunlight or certain chemicals. It matters to investors because a chronic, trigger-driven disease creates ongoing demand for approved drugs, diagnostic tests and care pathways, shaping market size, pricing power and regulatory risk much like a household appliance that needs regular replacement or maintenance rather than a one-time purchase.

AI-generated analysis. Not financial advice.

Webinar to be held Tuesday, December 2nd, at 8:00 am ET

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that the Company will host a webinar to present findings from its investigation into the anomalous results from the BEACON study in CSU reported in July, as well as preliminary data from the ETESIAN study in asthma. The webinar will include remarks from Jasper management as well as Dr. Martin Metz, M.D., Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, and lead EU investigator in the BEACON study. A live question and answer session will follow the formal presentation.

Registration details for the webinar are as follows:

Jasper Therapeutics Investor Webinar

Tuesday, December 2, 2025 - 8:00 am ET

Registration Link: Click Here

The presentation slides and a link to the live and archived webcast will also be available on the Events & News – Events page of Jasper's Investor Relations website.

About Jasper

Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU, and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in both CSU and CIndU. For more information, please visit us at www.jaspertx.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU and asthma and Jasper’s presentation of findings from its investigation into the anomalous results from the BEACON study in CSU reported in July and preliminary data from the ETESIAN study in asthma and the topics expected to be discussed during the webinar. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper’s investigation into the confounded efficacy results from the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts of the BEACON study in CSU may be inconclusive or may not lead to the anticipated conclusion; the risk that Jasper may be unable to raise capital to continue its operations and continue the BEACON study; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertherapeutics.com

Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com

Molly Devlin (media)
Real Chemistry
443-416-6675
mdevlin@realchemistry.com

FAQ

When is Jasper Therapeutics (JSPR) hosting the investor webinar on ETESIAN and BEACON findings?

The webinar is scheduled for Tuesday, December 2, 2025 at 8:00 am ET.

What will Jasper Therapeutics (JSPR) present in the December 2, 2025 webinar?

Jasper will present preliminary ETESIAN asthma data and findings from its investigation into anomalous BEACON CSU results.

Who will speak for Jasper Therapeutics (JSPR) at the December 2, 2025 webinar?

Presenters include Jasper management and Dr. Martin Metz, M.D., lead EU investigator in the BEACON study.

How can investors register for the Jasper Therapeutics (JSPR) December 2, 2025 webinar?

Investors must register via the provided registration link; details are on Jasper's investor events page.

Will the December 2, 2025 Jasper Therapeutics (JSPR) webinar be available after the live event?

Yes. Presentation slides and a link to the live and archived webcast will be posted on the company's Events page.